In this work, we use AAV9 22, a naturally-occurring serotype which has limited transport across the BBB, displays an inherent hepatotropism and has shown promise in treating several conditions, including SMA 31, Huntington's disease 32, and Rett syndrome 33. This evidence concerns the gene SMN1 and Rett syndrome.